PureTech Health PLC Brain Lymphatics Programme Published in Nature
26 July 2018 - 4:02PM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
26 July 2018
26 July 2018
PureTech Health plc
PureTech Health Collaborator Publishes in Journal Nature
Regarding New Insights into Key Role of Brain Lymphatics in
Alzheimer's and Other Neurodegenerative Diseases
Related intellectual property exclusively licensed to PureTech
Health and being advanced as part of growing internal research and
development division
PureTech Health plc (LSE: PRTC) ("PureTech Health"), a
clinical-stage biopharmaceutical company developing novel medicines
for dysfunctions of the Brain-Immune-Gut (BIG), today notes the
publication of foundational science in Nature which underlies its
new internal programme focused on treating central nervous system
(CNS) disorders via modulation of the brain's lymphatic system.
The approach is based on the work of Jonathan Kipnis, PhD,
Harrison Distinguished Teaching Professor and Chair, Department of
Neuroscience, and Director, Centre for Brain Immunology and Glia,
at the University of Virginia School of Medicine. In 2015, Dr
Kipnis published his original discovery of lymphatic vessels in the
brain in Nature. Building on that discovery, Dr Kipnis' latest
publication reveals the potential role of these lymphatic vessels,
including in Alzheimer's disease, Huntington's disease, and
age-associated cognitive decline. The publication presents
preclinical models that suggest modulation of lymphatic function in
the brain may prevent or delay diseases associated with aging.
"Dr Kipnis' original work completely changed the way we view
immune privilege in the brain - the unique biological properties
that protect certain areas of the body from inflammatory immune
responses," said Joseph Bolen, PhD, Chief Scientific Officer at
PureTech Health. "This new discovery once again offers novel
insights into the lymphatics' role in maintaining brain homeostasis
and suggests that neurodegeneration may be tied to drainage issues
in the brain. Because neurodegeneration is associated with so many
devastating conditions, these findings provide us with a unique
opportunity to develop treatments that address one of the world's
highest global disease burdens."
PureTech Health has exclusively licensed this intellectual
property from the University of Virginia (UVA) Licensing &
Ventures Group and is developing it in collaboration with Dr Kipnis
at UVA and as a part of PureTech's internal research and
development division, which is focused on lymphatics and immune
cell trafficking.
Dr Kipnis commented on this announcement, "Our work exploring
the function of lymphatic vessels has shed light on novel
therapeutic approaches that complement the lymphatics focus of
PureTech's research and development work. I look forward to
building on a great partnership with the team at PureTech Health to
further advance these findings and translate them into
first-in-class therapies that could fundamentally change the way we
intervene in neurodegenerative disease."
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. This division, which
includes the CNS lymphatics technology, has generated compelling
pre-clinical data and secured key intellectual property for its
lymphatic and immune cell trafficking programmes.
About the CNS Lymphatics Technology
The central nervous system (CNS) was previously thought to be
devoid of lymphatic vasculature; however, research published in
Nature in 2015 identified the meningeal lymphatic and glymphatic
systems as key maintenance organs within the brain. The biological
crosstalk at the CNS-immune interface has been further supported by
evidence published in Nature in 2018, which demonstrated that
modulation of lymphatic function in the brain may potentially
prevent or delay diseases associated with neurodegeneration,
including Alzheimer's disease, Huntington's disease, and
age-associated cognitive decline. These insights underlie
PureTech's approach to designing novel categories of therapeutics
to address debilitating and devastating CNS disorders.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG). The Company has
developed deep insight into the connection between these systems
and the resulting role in many chronic diseases, which represent
the majority of healthcare spend and have proven resistant to
established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech Health has developed new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions. Its Affiliates division includes
two product candidates that are preparing for potential regulatory
approval in the United States and Europe and a number of clinical
and pre-clinical programmes. These affiliates have developed
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading scientific
experts.
PureTech's Internal division (Ariya) is advancing a pipeline
fuelled by recent discoveries in lymphatics and immune cell
trafficking to modulate disease in a tissue-specific manner. These
programmes build on a new understanding of the transport and
biodistribution of various immune system components in order to
develop targeted therapies for diseases with major unmet needs
including cancer and autoimmune and neuroimmune disorders. One of
these programs, which is focused on the oral administration of
nucleic acids and other biologics using milk exosomes, is being
advanced in collaboration with Roche for the potential application
across their antisense oligonucleotides platform.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAVELFLVDFEBBX
(END) Dow Jones Newswires
July 26, 2018 02:02 ET (06:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024